Use of FLJ25416 gene
US8486905B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 5, 2008 |
| Grant date | Jul 16, 2013 |
| Priority date | — |
| Expiry date | Jun 24, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.